In practice, the slowing of stomach emptying adjusts within weeks, and propranolol isnt a drug where small changes in absorption produce meaningful changes in effect
The SURPASS clinical trial program, which evaluated tirzepatide in over 6,000 patients with type 2 diabetes, did not identify frequent urination as a statistically significant adverse event
: #RareDisease #SpecialtyPharmacy #PatientAccess #MedicationAdherence #PANTHERxRare Specialty Pharmacy Continuum To view or add a comment, sign in Recent IQVIA data show that more than half of novel specialty prescriptions never reach patients, and only a small portion remain on therapy after one year
Consult with your healthcare provider to determine a suitable maintenance plan based on your needs and health goals
Exenatide The FDA OKd exenatide in 2005, making it the first approved GLP-1 for Type 2 diabetes